Moderna reveals 2022 Israel supply agreement
Moderna Inc. published an official announcement regarding its new COVID-19 vaccine supply agreement with Israel for 2022 on Tuesday.
Chief Executive Officer of Moderna Stéphane Bancel stated that the Israel agreement marks the company’s first firm order for the 2022 supply. He added that the variant-specific booster vaccine candidates are currently undergoing human clinical trials and that the company hopes for positive results. As stipulated by the agreement, Israel has the option of purchasing doses of one variant-specific candidate alongside the current Moderna jabs.
Today’s announcement follows two prior agreements between Israel and Moderna wherein the company was to supply a total of 10 million doses. The current Moderna vaccine was approved for regular use by the Israeli Ministry of Health on January 4.
Get involved!
Comments